Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,789,000)	$ (27,924,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,289,000	1,062,000
Amortization of intangible assets	66,000	2,880,000
Stock-based compensation	2,276,000	7,423,000
Equity compensation for bonus awards and consulting services	108,000
Unrealized (gain) loss on marketable equity securities	(8,000)	485,000
Amortization of debt issuance costs		12,000
Change in fair value of contingent consideration	(16,947,000)	(17,157,000)
Change in fair value of Series A redeemable convertible preferred stock second tranche obligation		(352,000)
Impairment losses	6,761,000
Loss on disposal of discontinued operations	1,659,000
Loss on disposal and held for sale assets	1,283,000
Changes in operating assets and liabilities:
Accounts receivable	130,000	(553,000)
Prepaid expenses and other assets	784,000	(745,000)
Accounts payable and accrued liabilities	(4,193,000)	422,000
Accrued severance and liabilities from Chronix Biomedical acquisition		(1,317,000)
Lease assets and liabilities	(43,000)	(156,000)
Assets held for sale	(139,000)
Net cash used in operating activities	(18,763,000)	(35,920,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of equipment	354,000
Construction in progress and purchases of furniture and equipment	(17,000)	(3,538,000)
Cash sold in discontinued operations (Note 13)	(1,510,000)
Net cash used in investing activities	(1,173,000)	(3,538,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares	13,848,000	32,812,000
Financing costs to issue common shares	(427,000)	(389,000)
Proceeds from sale of redeemable convertible Series A preferred shares		4,875,000
Redemption of redeemable convertible Series A preferred shares	(1,118,000)
Financing costs to issue redeemable convertible Series A preferred shares		(93,000)
Proceeds from sale of common shares under at-the-market transactions		31,000
Financing costs for at-the-market sales		(1,000)
Repayment of loan payable		(1,325,000)
Repayment of financing lease obligations	(87,000)	(4,000)
Net cash provided by financing activities	12,216,000	35,906,000
NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH	(7,720,000)	(3,552,000)
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING	23,203,000	37,305,000
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING	15,483,000	33,753,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest		24,000
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities	$ 215,000	$ 1,032,000